{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:11:59Z","timestamp":1791994319152,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.esmoop.2026.106907","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:17:58Z","timestamp":1774556278000},"page":"106907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes of trifluridine\/tipiracil plus bevacizumab versus trifluridine\/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study"],"prefix":"10.1016","volume":"11","author":[{"given":"F.","family":"Moik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9184-4038","authenticated-orcid":false,"given":"F.","family":"Huemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Doleschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0927-6498","authenticated-orcid":false,"given":"H.","family":"Taghizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Reimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5180-0901","authenticated-orcid":false,"given":"S.M.","family":"Kostmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8350-4390","authenticated-orcid":false,"given":"M.","family":"Abdel Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1357-8712","authenticated-orcid":false,"given":"K.C.","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Supp\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bachleitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8317-5283","authenticated-orcid":false,"given":"R.","family":"Schaberl-Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0286-7001","authenticated-orcid":false,"given":"A.","family":"Amann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4462-3694","authenticated-orcid":false,"given":"R.","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2454-0362","authenticated-orcid":false,"given":"P.J.","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4216-2994","authenticated-orcid":false,"given":"T.","family":"Winder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Rumpold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2174-5613","authenticated-orcid":false,"given":"L.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3888-5401","authenticated-orcid":false,"given":"A.","family":"Gerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Seeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2026.106907_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106907_bib2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41571-024-00965-0","article-title":"Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm","volume":"22","author":"Cirac\u00ec","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106907_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2022.04.019","article-title":"Treatments after second progression in metastatic colorectal cancer: a pooled analysis of the TRIBE and TRIBE2 studies","volume":"170","author":"Rossini","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106907_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106907_bib5","first-page":"159","article-title":"Regorafenib is associated with increased skeletal muscle loss compared to TAS-102 in metastatic colorectal cancer","volume":"18","author":"Huemer","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106907_bib6","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.3390\/cancers12102812","article-title":"Hospitalizations and clinical outcome in metastatic colorectal cancer during regorafenib or TAS-102 therapy","volume":"12","author":"Huemer","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9863","key":"10.1016\/j.esmoop.2026.106907_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106907_bib8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2026.106907_bib9","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106907_bib10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in asian patients with previously treated metastatic colorectal cancer: the TERRA study","volume":"36","author":"Xu","year":"2018","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.esmoop.2026.106907_bib11","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106907_bib12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41591-023-02240-8","article-title":"Codon-specific KRAS mutations predict survival benefit of trifluridine\/tipiracil in metastatic colorectal cancer","volume":"29","author":"van de Haar","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106907_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"28","key":"10.1016\/j.esmoop.2026.106907_bib14","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106907_bib15","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106907_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106907_bib17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106907_bib18","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1001\/jamaoncol.2017.2797","article-title":"Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio","volume":"3","author":"Pak","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106907_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30908-2","article-title":"Trifluridine\/tipiracil in metastatic gastric cancer","volume":"20","author":"McCaw","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106907_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100511","article-title":"Effect of KRAS codon 12 or 13 mutations on survival with trifluridine\/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis","volume":"7","author":"Yoshino","year":"2022","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106907_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102945","article-title":"Impact of KRAS(G12) mutations on survival with trifluridine\/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial","volume":"9","author":"Tabernero","year":"2024","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106907_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102064","article-title":"Bevacizumab mitigates codon-specific effects of trifluridine\/tipiracil on efficacy outcome parameters in metastatic colorectal cancer","volume":"8","author":"Doleschal","year":"2023","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106907_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae277","article-title":"Clinical impact of TP53 functional mutations in patients with metastatic colorectal cancer treated with bevacizumab and chemotherapy","volume":"30","author":"Ruzzo","year":"2025","journal-title":"Oncologist"},{"issue":"28","key":"10.1016\/j.esmoop.2026.106907_bib24","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1200\/JCO.21.02506","article-title":"TP53 Sequencing and p53 immunohistochemistry predict outcomes when bevacizumab is added to frontline chemotherapy in endometrial cancer: an NRG oncology\/gynecologic oncology group study","volume":"40","author":"Thiel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106907_bib25","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1158\/1535-7163.MCT-16-0196","article-title":"TP53 Alterations correlate with response to VEGF\/VEGFR inhibitors: implications for targeted therapeutics","volume":"15","author":"Wheler","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106907_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12885-017-3955-4","article-title":"Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikament\u00f6se Tumortherapie)","volume":"18","author":"Huemer","year":"2018","journal-title":"BMC Cancer"},{"issue":"24","key":"10.1016\/j.esmoop.2026.106907_bib27","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer","volume":"392","author":"Elez","year":"2025","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.esmoop.2026.106907_bib28","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106907_bib29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41591-024-03352-5","article-title":"Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations","volume":"31","author":"Orcutt","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106907_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101614","article-title":"Real-world evidence of trifluridine\/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan","volume":"8","author":"Kagawa","year":"2023","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106907_bib31","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1038\/s41598-019-42069-1","article-title":"Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: a propensity score analysis","volume":"9","author":"Moik","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmoop.2026.106907_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejca.2021.03.040","article-title":"Gemcitabine\/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: a propensity score analysis","volume":"151","author":"Riedl","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.106907_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211039930","article-title":"Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis","volume":"13","author":"M\u00fcller","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"10395","key":"10.1016\/j.esmoop.2026.106907_bib34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:32:26Z","timestamp":1776699146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926008495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2059702926008495"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106907","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of trifluridine\/tipiracil plus bevacizumab versus trifluridine\/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106907"}}